Prognostic accuracy of MALDI-TOF mass spectrometric analysis of plasma in COVID-19

Author(s):Show less -

Lazari, Lucas Cardoso ^[1] ; Ghilardi, Fabio De Rose ^[2] ; Rosa-Fernandes, Livia ^[1] ; Assis, Diego M. ^[3] ; Nicolau, Jose Carlos ^[4] ; Santiago, Veronica Feijoli ^[1] ; Dalcoquio, Talia Falcao ^[4] ; Angeli, Claudia B. ^[1] ; Bertolin, Adriadne Justi ^[4] ; Marinho, Claudio R. F. ^[1] ; Wrenger, Carsten ^[1] ; Durigon, Edison Luiz ^[5] ; Siciliano, Rinaldo Focaccia ^[4] ; Palmisano, Giuseppe ^[1]

Affiliation

^[1] Univ Sao Paulo, Inst Biomed Sci, Dept Parasitol, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Inst Med Trop, Sao Paulo - Brazil

^[3] Bruker Brasil, Atibaia, SP - Brazil

^[4] Univ Sao Paulo, Heart Inst InCor, Med Sch, Sao Paulo - Brazil

^[5] Univ Sao Paulo, Inst Biomed Sci, Dept Microbiol, Sao Paulo - Brazil

• Document type: Journal article
• Source: LIFE SCIENCE ALLIANCE; v. 4, n. 8 AUG 2021.
• Web of Science Citations: 2

Abstract

SARS-CoV-2 infection poses a global health crisis. In parallel with the ongoing world effort to identify therapeutic solutions, there is a critical need for improvement in the prognosis of COVID-19. Here, we report plasma proteome fingerprinting that predict high (hospitalized) and low-risk (outpatients) cases of COVID-19 identified by a platform that combines machine learning with matrix-assisted laser desorption ionization mass spectrometry analysis. Sample preparation, MS, and data analysis parameters were optimized to achieve an overall accuracy of 92%, sensitivity of 93%, and specificity of 92% in dataset without feature selection. We identified two distinct regions in the MALDI-TOF profile belonging to the same proteoforms. A combination of SDS-PAGE and quantitative bottom-up proteomic analysis allowed the identification of intact and truncated forms of serum amyloid A-1 and A-2 proteins, both already described as biomarkers for viral infections in the acute phase. Unbiased discrimination of high-and low-risk COVID-19 patients using a technology that is currently in clinical use may have a prompt application in the noninvasive prognosis of COVID-19. Further validation will consolidate its clinical utility. (AU)

• FAPESP's process: 20/04705-2 - Diagnostic and prognostic study of SARS-CoV-2 and Influenza virus infection
• Grantee: José Carlos Nicolau
• Support Opportunities: Regular Research Grants
• FAPESP's process: 18/15549-1 - Post-translational modifications in Chagas Disease biological processes and diagnostics: novel methodological approaches and biological applications
• Grantee: Giuseppe Palmisano
• Support Opportunities: Research Grants - Young Investigators Grants - Phase 2
• FAPESP's process: 17/03966-4 - Targeting lipoic acid salvage and biosynthesis pathways in MRSA
• Grantee: Carsten Wrenger
• Support Opportunities: Regular Research Grants
• FAPESP's process: 15/26722-8 - Drug discovery against human infectious diseases
• Grantee: Carsten Wrenger
• Support Opportunities: Research Projects - Thematic Grants
• FAPESP's process: 18/20468-0 - Recrudescence of the malaria during pregnancy: effects and mechanisms
• Grantee: Cláudio Romero Farias Marinho
• Support Opportunities: Regular Research Grants
• FAPESP's process: 20/04923-0 - SARS-CoV-2 glycosylation: a blueprint structural insight for understanding COVID-19 pathogenesis
• Grantee: Giuseppe Palmisano
• Support Opportunities: Regular Research Grants
• FAPESP's process: 18/18257-1 - Multi-user equipment approved in grant 14/06863-3: HPLC system configured for analysis of carbohydrates, amino acidis, peptides and glycoproteins
• Grantee: Giuseppe Palmisano
• Support Opportunities: Multi-user Equipment Program